Regenerative Medicine News

April 4, 2017 – (NantKwest) – Viracta will use funds from the Series B financing to support the advancement of VRx-3996 into Phase 2 clinical studies for the treatment of Epstein Barr Virus-associated malignancies via Viracta’s proprietary viral gene activation therapeutic approach.
April 4, 2017 – (Sentien) – The Series A round will be used to fund initial clinical development of Sentien’s SBI- 101 for the treatment of acute kidney injury.
April 3, 2017 – (Alliqua) – Alliqua BioMedical, Inc. announced the closing of its previously announced underwritten offering of 9,473,250 shares of its common stock at a public offering price of $0.40 per share, with total gross proceeds to the Company of approximately $3.8 million.
March 30, 2017 – (Fred Hutch) – The Bezos family is offering this unprecedented gift to help Fred Hutch achieve its top strategic aim ― identifying and attracting more world-class talent to lead and propel the research priorities at the core of the Hutch’s new strategic plan.
March 30, 2017 – (Osiris) – “This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, Chief Scientific Officer at Osiris.
March 30, 2017 – (Pluristem) – Pluristem and Sosei CVC currently anticipate definitive agreements are to be finalized in the coming months, rather than by March 31, 2017 as previously announced.
March 29, 2017 – (TMC) – “This is a pivotal moment in our history,” he said. “The gift will provide significant resources to propel the rapid translation of medical discovery to transform patient care.”

Pages